[Immunohistochemical studies of the determination of the hormone receptor status of breast cancer].
Immunohistochemical examinations of 89 breast cancer specimens were performed using two different monoclonal antibodies. One marked the nuclear estrogen-receptor (ER) protein (anti-ER, Abbott), whereas the other marked an ER-related cytoplasmic protein (ER-D5 Amersham). Comparison of the results of the biochemical assay with those of the immunohistochemical markers revealed the following correlations: 75% anti ER and 71% ER-D5. Clinical follow-up studies are necessary to specify the relevance of these new immunohistochemical techniques in the anti-hormonal therapeutic management of breast cancer patients.
D000911:Antibodies, Monoclonal; D001940:Breast / Q000032:analysis; D001943:Breast Neoplasms / Q000032:analysis*; D002467:Cell Nucleus / Q000032:analysis; D003593:Cytoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D000911:Antibodies, Monoclonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Immunhistochemische Untersuchungen zur Bestimmung des Hormonrezeptorstatus von Mammakarzinomen.